Currently, the country is using two 'made-in India' jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.
An association of biotechnology scientists on Wednesday appealed to the Centre to approve Bt brinjal for commercial cultivation "without further delay" for the benefit of Indian farmers and consumers.
While financial institutions like banks not showing interest in investing in basic biotechnology research as they have long gestation periods, PE and VC funds too are not comfortable betting their money on research projects as they do not give an opportunity for a quick exit facility.
The company has received approval from the Drugs Controller General of India (DCGI) to market Itolizumab injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19.
The formula for success of farm economy is very simple -- farmers should be able to produce more from the same piece of land at reduced cost while minimising risk and be connected to market to get higher realisation for their produce, points out Siraj Chaudhry.
India's biotechnology industry has crossed the $1 billion mark in revenues.
The company has set an affordable ceiling price of USD 3 (around Rs 225) per dose, it added.
'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'
Clinical trials, agri-biotech and bio-fuels are becoming opportunities. There are a lot of growth drivers and trigger points which, she said, will deliver in the next five years.
National Woman Bioscientist Awards: 2003
In an interview with Nandita Datta she talks about biotechnology becoming the new buzzword and what it takes to build a successful career.
Joint Secretary in the Health Ministry Lav Agarwal claimed that India has been doing better than many other countries on the outcome ratio, which is the number of recoveries from coronavirus infection versus the number of deaths.
While virologists say theoretically the vaccine that works on Delta should work on the Delta Plus variant as well, more research is needed.
This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the 'capabilities and expertise' to manufacture the inactivated viral vaccines at commercial scale.
Shahid Jameel, recipient of Shanti Swarup Bhatnagar Prize for Science and Technology, also said that the country had already reached community transmission a long time ago.
The Indian biotechnology sector is poised for an exponential growth and would garner a global market share of 10 per cent in the next five years from the present one per cent.
Mukul Jain, enrolled in Life Sciences course, has been missing since January 8.
Approximately 72% people wear inappropriate sized footwear which is associated with all kind of foot problems.
Scientists associated with Indian SARS-CoV-2 Consortium on Genomics (INSACOG), the government panel that conducts research on different variants of the coronavirus, said they were surprised at noted virologist Shahid Jameel's decision to quit the group and wondered whether he was disillusioned with the government's handling of the pandemic.
Med Ad News is a global pharmaceutical magazine and is regarded as one of the most respected journals in the segment.
As states grapple with a shortage of coronavirus vaccines, the Centre on Thursday said that over two billion doses will be made available in the country in five months between August and December, enough to vaccinate the entire population.
Early data from its vaccine candidate 'mRNA-1273' showed it produced protective antibodies in a group of eight healthy volunteers, Moderna said. The other closely watched COVID-19 vaccine is the one being developed by scientists at Oxford University.
In a statement, the PMO said three vaccines are in advanced stages of development in India, out of which two are in Phase II and one is in Phase-III. It further said Indian Scientists and research teams are collaborating and strengthening the research capacities in neighbouring countries such as Afghanistan, Bhutan, Bangladesh, Maldives, Mauritius, Nepal and Sri Lanka.
The Indian Institute of Science, Bangalore, invites applications from Indian nationals for the DBT-Postdoctoral Fellowship for pursuing research in the frontier areas of biotechnology and applied biology.
The Serum Institute of India, the largest vaccine maker in the world, has been chosen by Oxford and its partner AstraZeneca to manufacture the vaccine once it is ready. Trials results for the first two phases were published earlier this month.
India's export revenue from biotechnology grew by 47 per cent to reach to 1.2 billion dollars in the financial year ended March 2007, a survey said.
Head of Epidemiology and Communicable diseases at the ICMR Dr Raman R Gangakhedkar said the apex health research body will begin a study on the effectiveness of the vaccine against coronavirus infection next week.
Today, an engineer from an average college can easily land an IT job. What about the biotech graduate, asks Rashmi Bansal?
Institute of Bioinformatics and Applied Biotechnology, Bangalore, invites applications for its Post-graduate Diploma in Bioinformatics and Laboratory Course in Biotechniques programmes.
'We must not compromise with the standard, the quality. We don't need to be the first to launch a drug but what we need is a Made in India vaccine that the entire world can rely on'
The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.
The two countries would be signing an MoU to foster research cooperation in biotechnology, the visiting premier said, addressing Indian industry captains at a conference organised by business chambers CII, FICCI and Assocham. \n\n
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances